Exclude Patient Type Detail Header
No
Footnote
<sup>1</sup> Drugs limited to those available in U.S., listed in alpha order. Regular and prn SAMA or SABA use improves FEV<sub>1</sub> and sx [A]; SABA+SAMA combos more effective than mono-tx [A]. LABAs and LAMAs improve dyspnea, reduce exac rate [A]. LAMAs reduce exac [A] and hospitalizations [B] more than LABAs; combos more effective than mono-tx [B]. Triple inhaled tx (ICS/LAMA/LABA) improves lung fxn, reduces exac compared w/ ICS/LABA, LABA/LAMA, or LAMA mono-tx [A].<br>
• <b>Not recommended:</b> antitussives [C]; long-term oral/inhaled steroid mono-tx [A]; theophylline, unless other bronchodilators unavailable/unaffordable [B]; vasodilators [B]; benzodiazepines. Insufficient evidence for music or breath relaxation tx.<br>
• No existing COPD med has conclusively been shown to modify lung-fxn decline long-term. However, a systematic review combining data from 9 studies showed a 5.0 mL/yr reduction in rate of FEV<sub>1</sub> decline compared w/ placebo.
<br><br>
<sup>2</sup> <b>Group A</b>=few sx, low exac risk. <b>Exac</b>=dyspnea and/or cough and sputum that worsen over <14 days.
<br><br>
<sup>3</sup> <b>Brief cessation counseling:</b><br>
• <b>Ask</b> about tobacco use at every visit for tobacco users; use office-wide identification system<br>
• <b>Advise</b> quitting in a clear, strong, personalized manner<br>
• <b>Assess</b> willingness to quit, determine when (eg, w/in next 30 days)<br>
• <b>Assist</b> w/ quit plan, including practical counseling, exploring social support, prescribing pharmaco-tx, educational resources<br>
• <b>Arrange</b> f/u in person or via phone, etc
<br><br>
<sup>4</sup> When community prevalence of COVID-19 high, restrict spirometry to pts requiring test for COPD dx and/or assessment of lung fxn for interventional/surgical procedures.
<br><br>
<sup>5</sup> Common comorbidities include CV dz, skeletal muscle dysfxn, metabolic syndrome, osteoporosis, depression, anxiety, lung CA.
<br><br>
<sup>6</sup> <b>COVID-19 mitigation strategies:</b><br>
• Follow basic infxn control measures<br>
• Wear a face covering in public<br>
• Consider sheltering in place
<br><br>
<sup>7</sup> Pts w/ COVID-19 should continue taking oral and inhaled resp meds for COPD.
• <b>Not recommended:</b> antitussives [C]; long-term oral/inhaled steroid mono-tx [A]; theophylline, unless other bronchodilators unavailable/unaffordable [B]; vasodilators [B]; benzodiazepines. Insufficient evidence for music or breath relaxation tx.<br>
• No existing COPD med has conclusively been shown to modify lung-fxn decline long-term. However, a systematic review combining data from 9 studies showed a 5.0 mL/yr reduction in rate of FEV<sub>1</sub> decline compared w/ placebo.
<br><br>
<sup>2</sup> <b>Group A</b>=few sx, low exac risk. <b>Exac</b>=dyspnea and/or cough and sputum that worsen over <14 days.
<br><br>
<sup>3</sup> <b>Brief cessation counseling:</b><br>
• <b>Ask</b> about tobacco use at every visit for tobacco users; use office-wide identification system<br>
• <b>Advise</b> quitting in a clear, strong, personalized manner<br>
• <b>Assess</b> willingness to quit, determine when (eg, w/in next 30 days)<br>
• <b>Assist</b> w/ quit plan, including practical counseling, exploring social support, prescribing pharmaco-tx, educational resources<br>
• <b>Arrange</b> f/u in person or via phone, etc
<br><br>
<sup>4</sup> When community prevalence of COVID-19 high, restrict spirometry to pts requiring test for COPD dx and/or assessment of lung fxn for interventional/surgical procedures.
<br><br>
<sup>5</sup> Common comorbidities include CV dz, skeletal muscle dysfxn, metabolic syndrome, osteoporosis, depression, anxiety, lung CA.
<br><br>
<sup>6</sup> <b>COVID-19 mitigation strategies:</b><br>
• Follow basic infxn control measures<br>
• Wear a face covering in public<br>
• Consider sheltering in place
<br><br>
<sup>7</sup> Pts w/ COVID-19 should continue taking oral and inhaled resp meds for COPD.
Detail Type
Text
Detail Text
Patient Type Detail Header (Long)
Inhaled BD<sup>1</sup> for COPD Group A<sup>2</sup> pts